PLA2G7 and diabetes mellitus: These predominantly non-diabetes studies investigated the following interventions over a mean (1SD) duration of 4.3 (1.5) years [BSR: 1.0–7.5 years]: statins (19 trials); fibrates (6 trials); n-3 fatty acids (2 trials); niacin (4 trials); CETP-inhibitor (2 trials); ezetimibe (1 trial); and Lp-PLA2 inhibitor (1 trial) (Table 4).